1 / 26

Review - 10 years of strengthening vaccines regulatory capacity

WHO Prequalification of Diagnostics, Medicines and Vaccines - 3rd Consultative Stakeholders Meeting. Review - 10 years of strengthening vaccines regulatory capacity

ryder
Download Presentation

Review - 10 years of strengthening vaccines regulatory capacity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WHO Prequalification of Diagnostics, Medicines and Vaccines - 3rd Consultative Stakeholders Meeting Review - 10 years of strengthening vaccines regulatory capacity David Wood and Lahouari Belgharbi, Quality Safety and Standards (QSS); Immunization, Vaccines and Biologicals (IVB); Family and Community Health (FCH); WHO HQ, Geneva 3rd WHO Prequalification Stakeholders Meeting

  2. Outline of the presentation • Key messages • Context • NRA strengthening • A 10-year review of progress • Constraints & challenges • Key recommendations

  3. Key messages • The vaccine development pipeline is especially buoyant; some extremely complex products are under development; specialist regulatory oversight is needed • Paradigms are changing in the vaccine world • WHO is committed to support countries to ensure and sustain that 100% of vaccines used in all national immunization programmes are of assured quality – NRA strengthening is one strategy to attain this goal 3rd WHO Prequalification Stakeholders Meeting

  4. Context 3rd WHO Prequalification Stakeholders Meeting

  5. Norms and standards Development of new vaccines Regulatory processes and quality WHO vaccine portfolio: from research to disease prevention Vaccine production, supply and financing Monitoring and disease burden assessment Immunization safety Vaccine delivery and accelerated programmes 3rd WHO Prequalification Stakeholders Meeting

  6. The Vaccine Pipeline & PQ vaccines 3rd WHO Prequalification Stakeholders Meeting

  7. Vaccine Manufacture shift from Industrial to Developing Countries • 1992, 100% of vaccine purchased by UNICEF from Industrial Nations • 2000, 53% of vaccines purchased are from Developing Nations, which include: 25% of Polio, 90% of Measles , 85% of Yellow Fever , 79% of Hep. B. • 1997-2000, 50% of Industrial Nations left BCG, DTP and TT manufacture • 7-10 manufacturer left measles production, leaving one country supplying >90% of the UNICEF needs – risk to vaccine security. 3rd WHO Prequalification Stakeholders Meeting

  8. Guided by Expert Committee on Standardization of Biologicals (ECBS) recommendations on safety, efficacy and quality issued in WHO Technical Report Series (TRS) World Health Organization's Goals Ensure that “100%” of vaccines used in all national immunization programmes are of assured quality • Definition of “Assured quality vaccines” • National Regulatory Authority (NRA) independent from vaccine manufacturer • NRA functional (system + 6 regulatory functions) • No unresolved problem with vaccines 3rd WHO Prequalification Stakeholders Meeting

  9. NRA strengthening 3rd WHO Prequalification Stakeholders Meeting

  10. Process to strengthen NRAsThe five step capacity building programme: 1)Benchmarking 2)NRA assessment 3)Planning to address gaps (IDP) 4)Implementation of plan, including technical inputs (GTN) 5)Monitoring and evaluation 3rd WHO Prequalification Stakeholders Meeting

  11. UN agency Procure Produce Regulatory system Marketing Autorization & Licensing activities Postmarketing: AEFI Lot release Laboratory access Regulatory inspections Authorization & monitoring of CTs National regulatory functions recommended for regulatory oversight of vaccines Source of vaccines Regulatory functions Regulatory functions For countries conducting Clinical Trials CTs : Clinical trials, UN: United Nations, AEFI: Adverse Events Following Immunization

  12. Strengthening vaccine regulatory capacity A 10-year review of progress, revision of NRA benchmarking system and a look to the future.Geneva 17-19 Dec 2008 Quality , Safety & Standards (QSS) Immunization, Vaccines & Biologicals (IVB)

  13. Country Status: country assessment of vaccine regulatory system conducted , September 1997 NRA assessment conducted & planned NRA assessment completed Not yet conducted The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

  14. Country Status: 86 country assessment of vaccine regulatory system conducted , Sept.1997 – Dec 2007 NRA assessment conducted & planned The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. NRA assessment completed Not yet conducted New assessment to be conducted in 2008

  15. The Global Training Network (GTN) trained 1200staff from 100countries since 1996 & was supported by WB, JICA, DFID,AusAid,WHO,EU,IDB,ADB,UNICEF,WHO Courses 1 –Regulatory inspections 2 - Quality Control Methods Participants 3 - Laboratory Quality Systems 4 - Licensing (for producing countries) 1. NRA Staff with Government Plan 5 - Animal Husbandry 2. Staff of Manufacturer with NRA 6 - Short Course in DTP & Strategic Plan 7 - Lot Release and Lab Access 3. NRA Staff and EPI Staff from vaccine 8 - Postmarketing Surveillance/AEFI procuring countries (for AEFI course only) Global resource to raise technical skills in the field of biological regulation: the Global Training Network since 1996 7-Health Canada 2,3-NIBSC Canada - NRA UK - NCL 2,5,6-NVI 1,9-IVP Netherlands - Producer U.S.A. - Producer 7- AFSSAPS - France - NRA 2- Biken 8- MOH Japan - Producer 1-Instituto Finlay -Producer Tunisia - MoH 3-CECMED - NRA Cuba 2-BioFarma Indonesia -Producer 5-CECAL/Fiocruz Brazil - Producer 4-TGA 8-University of Australia - NRA Cape Town South Africa -NRA Contract Work 9 - Licensing (for procuring countries) 10. Authorisation/Monitoring of clinical Trials

  16. Experts identified & recruited to conduct NRA assessments , 1997-2007 -NRA assessment started in EMR -HQ Staff seconded To EMRO - 86 NRA assessments - 76 follow up visits conducted - Fundraising increased: WHO, Australia, Japan, WB, DFID, USAID,EDCTP -HQ staff reassigned to HQ to coordinate NRA activities : -initial budget $44.000 Number of expeerts

  17. 350 Regulatory experts recruited from national regulatory authorities (Sept 1997- Dec.2007) NRA regulatory experts The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

  18. Databases : 8 modules developed for planning, assessment, experts & monitoring

  19. WEB site dedicated to NRA strengthening activities since 2004

  20. Global production & NRA assessments100% of countries with high production volume/capacity assessed 49 countries produce vaccines 44 countries produce consistent and important volume 5 countries stopped or inconsistent/very low volume/capacity 3rd WHO Prequalification Stakeholders Meeting Source: WHO, NRA assessment, as of December 2007

  21. Number of countries exercising all regulatory functions relevant to their source of vaccine, Dec.2007 84 Countries 65 Countries 44 Countries Number of countries

  22. Assured quality vaccines procured through WHO prequalification scheme , 2006 14 industrialized countries 6 developing countries 24 manufacturers 65 pre-qualified vaccines used in 112 countries 53% total population 13% population

  23. Constraints & Challenges Political commitment and support: • Some vaccine manufacturers do not believe or wish to have independent and stronger NRA oversight • Political commitment to support in country NRA activities is lacking in several countries Global supply of vaccine: • Risk of global shortage of critical vaccines in case of failure of NRA in producing countries to exercise all six functions 3rd WHO Prequalification Stakeholders Meeting

  24. Constraints & Challenges National capacity to regulate products or contribute to WHO NRA assessments: • Lack of regulatory experts with vaccines expertise in developing countries • Opportunity costs of mentoring and training of experts for assessments because of the limited number of assessments each expert performs • Government not always keen to release national experts for WHO assessments, training and follow up visits • Difficulties to identify and train team leader for country assessment as it requires in depth and wide scope expertise • Institutional Development Plan (IDP) not always followed and often re-assessment needed to update the IDP because of obsolete recommendations or changes in structure/staff • NRAs staff lack of expertise/skills to assess new products 3rd WHO Prequalification Stakeholders Meeting

  25. Key recommendations from 10 year review meeting NRA assessments have been key to assist countries to strengthen their regulatory system and develop plan (IDP) to meet prequalification requirements, the activities should continue by improving the following areas: • Experts: The standards of the experts, and their experience and understanding of the regulatory process, vary. Further consideration should be given to recruitment and training of experts for this work. • Improved synergies : between the WHO vaccines and medicines NRA assessment processes should be identified • Institutional Development Plan (IDP): needs to be ongoing, subject to regular (but not too frequent) review, and it needs to have built in to it sustained financial support and political will. • Decentralization: There needs to be increasing involvement of the WHO Regional Offices • Data management & analysis: data that have been generated have not been sufficiently analyzed to learn more about systems strengthening. 3rd WHO Prequalification Stakeholders Meeting

  26. WHO Prequalification of Diagnostics, Medicines and Vaccines - 3rd Consultative Stakeholders Meeting Review - 10 years of strengthening vaccines regulatory capacity David Wood and Lahouari Belgharbi, Quality Safety and Standards (QSS); Immunization, Vaccines and Biologicals (IVB); Family and Community Health (FCH); WHO HQ, Geneva 3rd WHO Prequalification Stakeholders Meeting

More Related